Peptide Profile

Thymosin Alpha-1

TA-1 / Thymalfasin

Off Label10 sourcesShop Thymosin Alpha-1

Overview

Composition

Synthetic 28-amino-acid peptide identical to the naturally occurring thymosin alpha-1 produced by the thymus gland

Mechanism of Action

Functions as an immunomodulator, enhancing T-cell maturation and differentiation, supporting natural killer (NK) cell activity, promoting cytokine production, and balancing Th1/Th2 immune responses

Primary Effects

Studied for immune support in infection, inflammation, and immunocompromised settings, with a comparatively large human clinical literature for selected approved indications outside the United States

Discovery & Background

First isolated in the early 1970s by Dr. Allan Goldstein from calf thymus extracts during research into thymic hormones and their role in T-cell development

Subsequently synthesized and characterized as a key mediator of adaptive immunity; by the 1980s–1990s, clinical trials began exploring its therapeutic potential, leading to its approval in countries like China, Italy, and others for hepatitis B and C treatment, as well as adjunctive use in certain cancers and immune deficiencies

Approved in several countries (though not by the FDA in the US) for specific indications such as chronic hepatitis; remains investigational or off-label in many places, including the US

Research Overview

One of the more clinically studied peptides, with decades of human trial data in selected regional indications

01
Demonstrated benefits in chronic viral infections (hepatitis B/C, HIV), sepsis, immunocompromised states (e.g., post-chemotherapy)
02
Used as an immune adjuvant in cancer therapy
03
Studies show improved T-cell responses, reduced viral loads, enhanced vaccine efficacy
04
Better outcomes in influenza or COVID-19 settings (in some exploratory work)
05
Approved in select regions for hepatitis and certain cancers
06
Anecdotal and off-label use often extends to chronic fatigue, autoimmune modulation, and general immune support

Approved in select regions for hepatitis and certain cancers; investigational or off-label in the US where it is not FDA-approved for any indication

Safety Considerations

Monitoring

Immune markers
Inflammatory symptoms and autoimmune activity
Viral loads
Complete blood count
Overall immune function

Side Effects

Common

Generally well-tolerated in many clinical-study settings
Low adverse-event rates reported in several longer-use studies
Transient redness, discomfort, or flu-like symptoms have been reported

Rare

Transient fatigue or flu-like symptoms

Contraindications

Limited contraindications based on extensive clinical data
Not FDA-approved in the US; remains investigational or off-label in many contexts
Long-term use should involve medical supervision with appropriate monitoring

Educational Notice

TA-1 has human clinical literature in selected approved indications outside the United States and is generally well-tolerated in those contexts, but it is not FDA-approved for use in the United States. It remains investigational or off-label in many settings, and long-term use should involve qualified medical supervision with appropriate monitoring.

References